Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149811 · ClinicalTrials.gov registry record
A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
A clinical trial, sponsored by Bausch Health Americas.
- Completed
- Registry status
- 27
- Enrollment target
NCT01149811 is a clinical trial that has completed, run by Bausch Health Americas. The registered enrollment target is 27 participants.
The verdict
NCT01149811 has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
Interventions
- DRUG Fipamezole ODT
- DRUG Fipamezole ODT Cohort 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149811
The ClinicalTrials.gov registry entry for NCT01149811 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fipamezole ODT is the first listed.
NCT01149811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01149811 about?
NCT01149811 is a clinical study titled "A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease". The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
What is the current status of trial NCT01149811?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01149811?
The interventions under investigation include: Fipamezole ODT (DRUG), Fipamezole ODT Cohort 2 (DRUG).
Who is sponsoring clinical trial NCT01149811?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.